RecruitingPhase 2NCT07277660
A Dose-ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Atopic Dermatitis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Galvokimig in Adult Study Participants With Moderate to Severe Atopic Dermatitis
Sponsor
UCB Biopharma SRL
Enrollment
160 participants
Start Date
Dec 29, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of the study is to evaluate the dose-response relationship of galvokimig compared with placebo in study participants with moderate-to-severe atopic dermatitis (AtD).
Eligibility
Min Age: 18 Years
Inclusion Criteria7
- Participant must be aged greater than or equal (≥)18 years at the time of signing the informed consent
- Participant has chronic atopic dermatitis (AtD) (according to American Academy of Dermatology Consensus Criteria) that has been present for at least ≥1 year prior to initiating the study (ie, signing of the informed consent form \[ICF\]) and with:
- validated Investigator Global Assessment (vIGA) score ≥3 at Screening and Baseline
- Eczema Area and Severity Index (EASI) score ≥16 at both Screening and Baseline
- Peak Pruritus Numerical Rating Scale (PP-NRS) score of ≥4 at both Screening and Baseline
- ≥10% body surface area (BSA) of AtD involvement at both Screening and Baseline
- Documented recent history (within 6 months prior to Screening) of inadequate response to treatment with topical medications, or study participants for whom topical treatments are otherwise medically inadvisable (eg, due to important side effects or safety risks) and who are candidates for systemic therapy
Exclusion Criteria8
- Participant has any history or presence of any medical or psychiatric condition, physical examination finding, laboratory test result, or electrocardiogram (ECG) signal that, in the opinion of the investigator, could constitute a risk when taking the study intervention; or interfere with the interpretation of data and could jeopardize or would compromise the study participant's ability to participate in this study
- Active dermatologic conditions that may confound the diagnosis of AtD or would interfere with assessment of treatment, such as but not limited to scabies, seborrheic dermatitis, cutaneous lymphoma, ichthyosis, psoriasis, active allergic or irritant contact dermatitis
- Presence or family history (first degree) of inflammatory bowel disease (includes Crohn's disease and ulcerative colitis)
- History of chronic or recurrent infections, or a serious or life-threatening infection within the 6 months prior to the Baseline (including herpes zoster) as judged by the investigator
- Previous treatment with galvokimig
- Participant has relevant safety events to one or more interleukin (IL)-13 biologic response modifiers (ie, dupilumab, tralokinumab and lebrikizumab) that resulted in discontinuation and change of treatment
- All systemic therapies (other than biologics), topical therapies and other treatments for AtD must be discontinued at least 4 weeks prior to Baseline
- Treatment with biologic agents must discontinued at least 3 months prior to baseline
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALGalvokimig
Drug: Galvokimig Pharmaceutical form: Solution for injection
DRUGPlacebo
Drug: Placebo Pharmaceutical form: Solution for injection
Locations(62)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07277660
Related Trials
Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis
NCT072629831 location
Metabolic Profiling of Immune Responses in Immune-mediated Diseases
NCT048648861 location
A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
NCT06389136127 locations
French Prospective Observational Study in Patients Eligible for Systemic Therapy for Atopic Dermatitis (AD)
NCT0683745462 locations
Natural History and Genetics of Food Allergy and Related Conditions
NCT025048531 location